DNA Sequencing Market Report 2026

The dna sequencing market size has grown rapidly in recent years. It will grow from $15.8 billion in 2025 to $18.35 billion in 2026 at a compound annual growth rate (CAGR) of 16.2%. The growth in the historic period can be attributed to human genome project completion, declining sequencing costs, academic genomics research growth, pharmaceutical r&d demand, early adoption of sanger sequencing.

The dna sequencing market size is expected to see rapid growth in the next few years. It will grow to $34.15 billion in 2030 at a compound annual growth rate (CAGR) of 16.8%. The growth in the forecast period can be attributed to precision medicine expansion, population genomics initiatives, ai-enabled data analysis, oncology diagnostics growth, clinical sequencing reimbursement support. Major trends in the forecast period include rising adoption of next-generation sequencing technologies, expansion of sequencing in clinical diagnostics, growing use in cancer and rare disease research, integration of sequencing with bioinformatics platforms, increasing demand for high-throughput sequencing services.

The rising prevalence of cancer is expected to drive the growth of the DNA sequencing market in the coming years. Cancer is characterized by the uncontrolled growth and spread of abnormal cells that can invade or destroy healthy tissues in various organs. The increasing incidence of cancer is driven by factors such as aging populations, lifestyle-related risk factors, environmental exposures, and improved detection methods. The DNA sequencing market supports this trend by enabling the identification of genetic mutations, providing a deeper understanding of tumor biology, and informing personalized treatment decisions that enhance patient outcomes. For example, in January 2024, the American Cancer Society, a US-based nonprofit cancer advocacy organization, reported that cancer cases rose to 2,001,140 in 2024, up from 1,958,310 in 2023, representing a 2.19% increase. Therefore, the growing prevalence of cancer is fueling the expansion of the DNA sequencing market.

Companies in the global DNA sequencing market are focusing on developing innovative platforms, including compact, cost-effective benchtop sequencers and real-time analysis solutions, to improve accessibility, accelerate turnaround times, and increase the scalability of genomic testing. These advanced sequencing platforms are next-generation instruments and software systems designed to lower the cost per genome, increase throughput, support decentralized testing, and provide faster results for both clinical and research applications. For instance, in October 2024, Illumina Inc., a US-based biotechnology company, launched its MiSeq i100 gene sequencers, which are smaller, lower-cost benchtop devices capable of delivering results in approximately four hours, priced at USD 49,000 for the base model. These systems make high-throughput sequencing more accessible to a wider range of research and testing laboratories, driving innovation in the DNA sequencing market. The compact design ensures improved efficiency while maintaining data quality, allowing smaller institutions to adopt advanced sequencing technologies previously beyond reach.

In March 2024, Clinical Microbiomics, a Denmark-based contract research organization, acquired DNASense ApS for an undisclosed amount. Through this acquisition, Clinical Microbiomics aims to enhance its long-read DNA and RNA sequencing capabilities, enabling more detailed exploration of microbiome complexities and accelerating progress in microbiome and metabolome research. DNASense ApS is a Denmark-based microbiome CRO specializing in long-read DNA and RNA sequencing technologies.

Major companies operating in the dna sequencing market are F. Hoffmann-La Roche Ltd, Abbott Laboratories Inc., Thermo Fisher Scientific Inc., Danaher Corporation, Merck KGaA, Siemens Healthineers AG, Eurofins Scientific SE, Agilent Technologies Inc., Illumina Inc., PerkinElmer Inc., Bio-Rad Laboratories Inc., QIAGEN N.V., BGI Genomics, Myriad Genetics Inc., Natera Inc., 10x Genomics Inc., GenScript Biotech Corporation, Novogene Corporation, Twist Bioscience, Genewiz LLC, Oxford Nanopore Technologies Ltd., Pacific Biosciences of California Inc., Macrogen Inc., LI-COR Inc., MGI Tech Co. Ltd., Zymo Research Corporation, Igenomix, Codex DNA, GenapSys Inc., SeqOnce Biosciences Inc.

North America was the largest region in the DNA sequencing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the dna sequencing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the dna sequencing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the DNA sequencing market by increasing costs of imported sequencing instruments, flow cells, reagents, and analytical software. Hospitals and research institutes in North America and Europe are most affected due to reliance on advanced imported platforms, while Asia-Pacific faces higher infrastructure costs. These tariffs increase sequencing expenses but also encourage regional manufacturing and localized supply chains.

The dna sequencing market research report is one of a series of new reports that provides dna sequencing market statistics, including dna sequencing industry global market size, regional shares, competitors with a dna sequencing market share, detailed dna sequencing market segments, market trends and opportunities, and any further data you may need to thrive in the dna sequencing industry. This dna sequencing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

DNA sequencing is the process of determining the exact order of nucleotides - adenine, cytosine, guanine, and thymine - in a DNA molecule. It is a key technique in molecular biology and genetics that enables scientists to decode the genetic information within an organism’s DNA.

The main products in DNA sequencing include instruments, consumables, and services. Instruments are specialized tools designed to perform delicate or precise tasks, and DNA sequencing instruments automate and execute the steps involved in sequencing DNA samples. The technologies used include third-generation DNA sequencing, next-generation sequencing, and Sanger sequencing, which are applied in diagnostics, biomarker and cancer research, reproductive health, personalized medicine, forensics, and other areas. These products and services are utilized by hospitals and healthcare organizations, academic and research institutions, pharmaceutical and biotechnology companies, and other end users.

The DNA sequencing market consists of revenues earned by entities by providing bioinformatics and data analysis software and sequencing services. The market value includes the value of related goods sold by the service provider or included within the service offering. The DNA sequencing market also includes sales of DNA sequencing kits, sequencing reagents, and laboratory equipment used in providing DNA sequencing services. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.